Rubius Therapeutics Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Rubius Therapeutics.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Biotechs earnings growth | 27.6% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
Recent updates
Rubius Therapeutics GAAP EPS of -$0.49 beats by $0.03
Aug 09Rubius: Poor Data, Punishing Environment, Beaten Stock
Jun 19Rubius Looks Attractive Before AACR Data Readout
Mar 21Are Rubius Therapeutics, Inc. (NASDAQ:RUBY) Investors Paying Above The Intrinsic Value?
Oct 28Our Read On Rubius Therapeutics
Jul 11Rubius Therapeutics EPS beats by $0.02
May 10Have Insiders Been Buying Rubius Therapeutics, Inc. (NASDAQ:RUBY) Shares?
Feb 25Rubius Therapeutics (RUBY) Presents At 39th Annual Healthcare Conference - Slideshow
Jan 14Rubius Therapeutics EPS misses by $0.01
Nov 09Rubius Therapeutics' RTX-321 shows dual mechanism of action in HPV-positive cancers
Oct 28In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Rubius Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2022 | N/A | -180 | -155 | -150 | N/A |
9/30/2022 | N/A | -215 | -161 | -155 | N/A |
6/30/2022 | N/A | -201 | -159 | -153 | N/A |
3/31/2022 | N/A | -207 | -159 | -154 | N/A |
12/31/2021 | N/A | -197 | -149 | -145 | N/A |
9/30/2021 | N/A | -182 | -142 | -138 | N/A |
6/30/2021 | N/A | -174 | -136 | -133 | N/A |
3/31/2021 | N/A | -162 | -130 | -126 | N/A |
12/31/2020 | N/A | -168 | -133 | -128 | N/A |
9/30/2020 | N/A | -172 | -144 | -126 | N/A |
6/30/2020 | N/A | -178 | -153 | -126 | N/A |
3/31/2020 | N/A | -179 | -167 | -128 | N/A |
12/31/2019 | N/A | -163 | -151 | -110 | N/A |
9/30/2019 | N/A | -146 | -132 | -101 | N/A |
6/30/2019 | N/A | -126 | -121 | -90 | N/A |
3/31/2019 | N/A | -107 | -89 | -70 | N/A |
12/31/2018 | N/A | -89 | -73 | -58 | N/A |
9/30/2018 | N/A | -80 | -60 | -48 | N/A |
6/30/2018 | N/A | -65 | -38 | -35 | N/A |
3/31/2018 | N/A | -54 | -33 | -30 | N/A |
12/31/2017 | N/A | -45 | -24 | -22 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if RUBY's forecast earnings growth is above the savings rate (2.2%).
Earnings vs Market: Insufficient data to determine if RUBY's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if RUBY's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if RUBY's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if RUBY's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RUBY's Return on Equity is forecast to be high in 3 years time